HUTCHMED Achieves Strong First Half Results with 23% Growth in Oncology Revenue
Hutchmed, a leading biopharmaceutical company, has reported strong first half results for 2026. The company's oncology revenue grew by 23%, reaching $162 million, driven by the success of its key products ELUNATE and SULANDA.
ELUNATE, Hutchmed's flagship product, saw a remarkable growth rate of over 40% in China, with sales exceeding $121 million. The company's Deputy CFO, Lorenso Chiu, highlighted that this performance is attributed to the product's strong market position and its inclusion in the National Reimbursement Drug List (NRDL). Hutchmed has also received approval for ELUNATE's use in second-line rectum cancer (RCC), providing further growth opportunities.
Another key driver of Hutchmed's success is SULANDA, which achieved strong growth in the first half, driven by its inclusion in the CSCO guideline for the treatment of neuroendocrine tumors (NET). The company's focus on top-tier cities and top hospitals has contributed to this growth. Hutchmed's Head of Commercial, George Yuan, emphasized that there is still room for expansion, particularly in terms of geographic reach and reimbursement.
FRUZAQLA, Hutchmed's flagship product globally, saw a 40% growth in in-market sales, with a 70% increase in ex-U.S. markets. The company's Acting CEO and CFO, Johnny Cheng, noted that this strong performance has resulted in an upgrade of Takeda's fiscal year guidance to 25%. Hutchmed also received two approved label expansions for fruquintinib for RCC and savolitinib for GC.
Hutchmed's R&D expenses increased to $79 million, reflecting the company's investment in global phase I trials of its ATTC assets. The company continues to be profitable, with net income reaching $16 million. Its cash reserve stands at a healthy $1.4 billion, providing a solid foundation for future growth.
Looking ahead, Hutchmed is poised for further success, with three NDAs in China under priority review and three phase I clinical trials underway. The company's innovative pipeline includes two first-in-class assets that have entered the clinic, as well as HMPL-A830, which has cleared its IND and will be entering the clinic in the second half.
With a strong track record of innovation and execution, Hutchmed is well-positioned to capitalize on emerging trends in oncology treatment. As the company continues to drive growth through its pipeline and commercial operations, investors and analysts alike are likely to take note of these promising developments.
